TORONTO, ON / ACCESS Newswire / January 12, 2026 / NextSource Materials Inc. (TSX:NEXT)(OTCQB:NSRCF) ("NextSource" or the "Company") is pleased to announce that it has finalized multiple term sheets with strategic investors to fund Phase 1 of the Company's proposed Battery Anode Facility ("BAF") in the Industrial City of Abu Dhabi in the UAE. These term sheets indicate substantial progress in the Company's strategic financing process and further reinforces the Company's path towards the final investment dec ...

Core Viewpoint - Silver Bullet Mines Corp. (SBMI) is optimistic about the potential of the Washington Mine in Idaho, believing it could become a significant mining operation again based on recent exploration results and historical data [1]. Group 1: Exploration and Findings - The geological team has identified historical workings at the Washington Mine, particularly the original high-grade gold discovery area, with samples showing a red hue associated with gold [2]. - Down dip portions of the gold shoot are documented and may serve as high-priority drill targets to outline the extension of the original high-grade gold discovery from the early 1890s, which was purported to be 1 oz/ton [3]. - Historical reports indicate that the Subrosa Adit at the Washington Mine had silver grades of 32 oz/ton and gold grades of 0.13 oz/ton over 65 feet, with current efforts focused on safely opening this adit for sampling [4]. Group 2: Current Operations and Future Plans - The company has engaged a contract miner to expose the Berger Vein at surface, with ongoing detailed mapping and soil sampling indicating the presence of fine gold [5]. - A plan for underground mining is being developed, targeting a significant bulk sample for processing in the coming weeks, which may lead to a resource report compliant with NI 43-101 standards [6]. Group 3: Financing and Use of Proceeds - SBMI has closed a strategic financing round, issuing 6,782,143 units at $0.21 per unit, raising gross proceeds of $1,424,250, with cash commissions of $43,379 and additional finders warrants [7]. - Proceeds from the financing will be allocated to further site work at the Super Champ, expand the King Tut Gold Mine footprint, advance the Washington Mine, and for general working capital [8].

Core Viewpoint - Silver Bullet Mines Corp. has commenced daily processing of high-grade silver and gold mineralized material from the Super Champ Mine in Arizona, indicating a significant operational advancement for the company [1][2]. Group 1: Production and Processing - The company is processing over six tons per hour for eight hours a day, five days a week, with plans to increase production hours by adding another shift [2]. - The head grade of the material is reported to be over 28 ounces per ton of silver, with a recovery rate of 89% [3][5]. - The concentrate grade of the Super Champ material has been announced at 530 ounces per ton of silver [3]. Group 2: Sales and Financial Arrangements - All immediate production from the Super Champ Mine is committed to a third-party buyer under a Firm Offer, which includes an initial payment of 90% of the estimated value of the concentrate [6]. - The company has entered into a strategic financing arrangement through a non-brokered private placement of Units, raising $1,120,800 at a premium price of $0.21 per Unit [10]. Group 3: Safety and Infrastructure - The company has ensured the safety of the mining operations by timbering the entire 125-foot lower adit and moving over 10,000 tons of material from the upper adit [7].

Core Insights - Rein Therapeutics has entered into two strategic financing agreements with Yorkville Advisors Global, LP, potentially providing access to up to $21 million in capital to support its clinical trials and pipeline advancement [1][2]. Financing Details - The financing consists of a $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing, and a $15 million standby equity purchase agreement (SEPA) that can be utilized at the company's discretion over 36 months [9]. - The pre-paid advance facility allows for up to $6 million to be drawn in mutually agreed tranches over the next twelve months, with each advance purchased at a 5% discount and repayable in common stock if requested by Yorkville [9]. - The SEPA gives Rein the option to sell up to $15 million of common stock over 36 months, contingent upon an effective registration statement [9]. Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [7]. - The lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in clinical development for idiopathic pulmonary fibrosis (IPF) [7]. - Rein's second product candidate, LTI-01, has completed Phase 1b and Phase 2a clinical trials for loculated pleural effusions and has received Orphan Drug Designation in both the U.S. and E.U. [7].